ECTS Abstracts (2015) 1 P389

Effects of Osteum, a Natural Ingredient, Containing Micellar Calcium, Vitamin D and K2, on Bone Mineral Density

Anne Blais1, Laure Gosse de Gorre2, Nicolas Valnaud1, Stépnanie Dayot1, Alain Baniel2 & Daniel Tomé1


1UMR914 INRA-AgroParisTech, Paris, France; 2Ingredia SA, Arras, France.


The aim of postmenopausal osteoporosis treatment is to decrease bone resorption and/or increase bone formation. Because of the slow bone turnover, osteoporosis prevention and therapies are long-lasting, implying great costs and poor compliance. Even if the effect of nutrition on bone is not as marked as that of pharmaceutical agents, it can be of great help. The nutritional intervention can be done alone preventively or as an adjuvant therapy in more severe cases. Some nutritional components such as calcium and vitamin D are recognised to have a positive effect on bone. The purpose of our study was to demonstrate the efficiency of OsteumTM, a natural ingredient including micellar calcium, vitamin D and K2, to improve bone mineral density (BMD). The in vitro study, using primary murine bone cells, showed that OsteumTM does not modulate cell growth but that it is able to stimulate osteoblast differentiation as shown by increase ALP activity and mineralisation and to inhibit osteoclast’s differentiation and resorption activity as shown by reduction of bone resorption. In vivo, using a model of ovariectomised mice, we showed that BMD was dose-dependently improved after OsteumTM ingestion. We also report increased osteoblast activity as shown by increase of ALP activity and decreased osteoclastogenesis as shown by reduced CTX activity. Improvement in BMD was observed after an intervention period of at least 8 weeks. This suggests that the acute effect of OsteumTM is mild but, when chronically ingested, the effect was found to be significant. Our results show that a dairy product providing not only calcium and vitamin D but also vitamin K is more efficient than calcium and vitamin D alone for BMD improvement.

Disclosure: The authors declared no competing interests.

Physical Perfomance and Risk of Fall in Elderly People with Severe Osteoporosis:

Background: This study evaluated the differences in physical performance and risk of fall in old oldest people affected by severe osteoporosis.

Methods: The subjects were all ≥ 85:45 women (mean age 88+3) and 6 men (mean age 88+2) affected by severe osteoporosis. In 7 women and 1 man we discovered a new spinal fracture after treatment. 38 women and 3 men had multiple spinal fractures (>3).The subjects were prescribed teriparatide treatment (PTH 1-34).The design of the study included at T0-T24:1) spine and hip DEXA densitometry; 2) spine X-ray with morphometry; 3) Blood tests. The physical performance was assessed through the Short Physical Performance Battery (SPPB) which results in a combination of a balance test according to 3 increasingly difficult positions, a walking test on a 4-metre-course and a standing-up test from a chair, and whose final SPPB score was comprised between 0 and 12.The Tinetti balance and gait Scale inspects the balance and the gait and shows a variability in score:score≤1 indicates non walking; 2<score<19 walking but with a high risk of fall; score≥ 20 walking with a low risk of fall.

Results: At T0 we considered:1)Short Physical Performance Battery Geriatric:mean score 7 in 78.9% subjects (p<0.05); 2)Tinetti balance and gait scale:mean score 8 (high risk of fall) 83.8% subjects (p<0.5);mean score 1 (non walking) 16.2% subjects (p<0.5).At T24 we evaluated:1) Short Physical Performance Battery:mean score 9 in 61.3% subjects (p<0.05);2) Tinetti balance and gait scale:mean score 14 (high risk of fall) 93.1% subjects (p<0.5),mean score 1 (non walking) 6.9% (p<0.5). At T24 in all subjects we detected no new spine fractures through spine X-rays and morphometry.

Conclusion: Since a reduced physical performance and an increase in the risk of fall indicate frailty in the elderly affected by severe osteoporosis, we inspected, after teliparatide treatment (PTH 1-34), the markers’ severity variations.

Disclosure: The authors declared no competing interests.

Article tools

My recent searches

No recent searches.